Page last updated: 2024-12-09

thiohydantoins

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thiohydantoins: Sulfur analogs of hydantoins with one or both carbonyl groups replaced by thiocarbonyl groups. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1274030
CHEMBL ID1958109
SCHEMBL ID27418
SCHEMBL ID17153849
MeSH IDM0021357

Synonyms (52)

Synonym
2-thioguidanthion
einecs 207-977-4
ai3-61106
2-thioxo-4-imidazolidinone
brn 0110599
nsc 11772
thiohydantoin
hydantoin, 2-thio-
usaf be-25
wln: t5mymv ehj bus
nsc-11772
503-87-7
4-imidazolidinone, 2-thioxo-
2-thiohydantoin
nsc11772
2-thiohydantoin, 99%
thiohydantoins
STK202136
2-thioxoimidazolidin-4-one
2-sulfanylideneimidazolidin-4-one
AKOS000120714
A828095
CHEMBL1958109
unii-cp2ph1a61r
cp2ph1a61r ,
5-24-05-00241 (beilstein handbook reference)
FT-0613441
S5613
AKOS017268991
SCHEMBL27418
DTXSID2060121
W-202893
glycine thiohydantoin
2-thioxo-4-imidazolidinone #
SCHEMBL17153849
mfcd00005277
CS-W013612
bdbm50207238
imidazolidin-4-one-2-thione
4-oxo-2-thioxoimidazolidine
VS-14145
EN300-17269
BBL037427
2-thioimidazol-4-one
8-fluoro-3,4,-dihydro-2h-benzo[1,4]oxazinehydrochloride
D97424
2-thiohytantoin
GEO-04515
HY-W012896
2-thioxotetrahydro-4h-imidazol-4-one
SY078823
Z56900799

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Most of the patients discontinued study treatment (n=33) due to disease progression (n=11 [22%]) or adverse events (AEs) (n=9 [18%])."( Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Alumkal, JJ; Antonarakis, ES; Bandekar, R; Berry, WR; Chow Maneval, E; de Boer, CJ; Higano, CS; Liu, G; Rathkopf, DE; Ryan, CJ; Shore, ND; Smith, MR; Yu, MK, 2016
)
0.43
"In high-risk nmCRPC patients, apalutamide was safe with robust activity based on durable PSA responses and disease control."( Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Alumkal, JJ; Antonarakis, ES; Bandekar, R; Berry, WR; Chow Maneval, E; de Boer, CJ; Higano, CS; Liu, G; Rathkopf, DE; Ryan, CJ; Shore, ND; Smith, MR; Yu, MK, 2016
)
0.43
" Odds ratios (ORs) of reported adverse events (AEs) and baseline-to-follow-up least squares mean differences in HRQoL [measured with Functional Assessment of Cancer Therapy-Prostate (FACT-P) score] with 95% credible intervals were re-estimated for SPARTAN arms using weighted population and indirectly compared with those in PROSPER through a Bayesian framework."( Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury, S; Dearden, L; Diels, J; Hadaschik, BA; Joniau, S; Lefebvre, P; Liu, J; McQuarrie, K; Oudard, S; Pilon, D; Sermon, J; Uemura, H; Van Sanden, S, 2020
)
0.56
" No increase in mineralocorticoid excess-related adverse events was observed."( Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Abrams, C; Attard, G; Chi, KN; Chien, C; de Jonge, MJA; de Wit, R; Friedlander, TW; Hellemans, P; Jiao, JJ; Posadas, EM; Saad, F; Yu, MK, 2020
)
0.56
" Univariate and multivariate logistic regression models assessed the relationship between apalutamide and N-desmethyl-apalutamide exposure and common treatment-emergent adverse events including fatigue, fall, skin rash, weight loss, and arthralgia."( Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
Ackaert, O; Chien, C; Lee, JY; Mainwaring, P; Olmos, D; Ouellet, D; Perez-Ruixo, C; Perez-Ruixo, JJ; Small, EJ; Smith, MR; Uemura, H; Yu, MK, 2020
)
0.56
" The exploratory exposure-safety analysis supports dose reductions in patients experiencing adverse events."( Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
Ackaert, O; Chien, C; Lee, JY; Mainwaring, P; Olmos, D; Ouellet, D; Perez-Ruixo, C; Perez-Ruixo, JJ; Small, EJ; Smith, MR; Uemura, H; Yu, MK, 2020
)
0.56
"2%) had grade 3/4 treatment-emergent adverse events, the most common being thrombocytopenia (26."( Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E, 2021
)
0.62
"The most recent overall survival (OS) and adverse event (AE) data have not been compared for the three guideline-recommended high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treatment alternatives."( Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Briganti, A; Chun, FKH; Collà Ruvolo, C; Graefen, M; Karakiewicz, PI; Kluth, LA; Mandel, P; Montorsi, F; Nocera, L; Saad, F; Shariat, SF; Tian, Z; Tilki, D; Wenzel, M; Würnschimmel, C, 2022
)
0.72
"Several novel androgen receptor (AR)-inhibitors have been introduced for nonmetastatic castration-resistant prostate cancer (nmCRPC) treatment, with the improvement of survival outcomes which need to be balanced against the risk of adverse events."( A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
Fragomeno, B; Massari, F; Merler, S; Mollica, V; Morelli, F; Oderda, M; Rizzo, A; Santoni, M; Sorgentoni, G; Taveri, E, 2022
)
0.72
" We extracted data on the trial and patient characteristics, and the following primary outcomes: all-cause mortality, the ratios of virological cure, and treatment-emergent adverse events."( Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.
Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G, 2021
)
0.62
" We aim to characterize apalutamide-related dermatological adverse events (dAEs) and management."( Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
Dranitsaris, G; Kollmeier, MA; Kraehenbuehl, L; Lacouture, ME; McBride, SM; Moy, A; Pan, A; Rathkopf, DE; Reingold, RE; Scher, HI; Xiao, H; Zhao, JL, 2022
)
0.72
"Second-generation androgen receptor inhibitors (ARIs) have been associated with adverse events (AEs) such as fatigue, falls, fractures, and rash in non-metastatic castration-resistant prostate cancer (nmCRPC) patients as identified in clinical trials."( Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
Appukkuttan, S; Corman, S; Gnanasakthy, K; Hussain, A; Jiang, S; Kebede, N; Macahilig, C; Varghese, D; Waldeck, R, 2022
)
0.72
" However, risk factors for and the timing of the onset of apalutamide-related cutaneous adverse events remain unclear."( Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.
Asahina, A; Egawa, S; Hata, K; Katsuta, M; Kimura, T; Murakami, M; Nobeyama, Y; Onuma, H; Sugaya, S; Tashiro, K; Watanabe, Y; Yamamoto, T; Yanagisawa, T, 2022
)
0.72
"7%) developed cutaneous adverse events."( Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.
Asahina, A; Egawa, S; Hata, K; Katsuta, M; Kimura, T; Murakami, M; Nobeyama, Y; Onuma, H; Sugaya, S; Tashiro, K; Watanabe, Y; Yamamoto, T; Yanagisawa, T, 2022
)
0.72
"A lower body weight is a significant risk factor for apalutamide-related cutaneous adverse events and their onset is within 6 months of initiation of therapy."( Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.
Asahina, A; Egawa, S; Hata, K; Katsuta, M; Kimura, T; Murakami, M; Nobeyama, Y; Onuma, H; Sugaya, S; Tashiro, K; Watanabe, Y; Yamamoto, T; Yanagisawa, T, 2022
)
0.72
" Logistic regression analysis assessed the relationships between apalutamide exposure and selected clinically relevant adverse events (n = 1051)."( Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
Ackaert, O; Agarwal, N; Chi, K; Chien, C; Chowdhury, S; Karsh, L; Lopez-Gitlitz, A; McCarthy, S; Ruixo, CP; Ruixo, JP; T'jollyn, H, 2022
)
0.72
" Dose reductions may improve these adverse events, based on an individual risk-benefit approach."( Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
Ackaert, O; Agarwal, N; Chi, K; Chien, C; Chowdhury, S; Karsh, L; Lopez-Gitlitz, A; McCarthy, S; Ruixo, CP; Ruixo, JP; T'jollyn, H, 2022
)
0.72
"Apalutamide-associated skin adverse events are more common in the Japanese than in the global population."( Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Dainichi, T; Daizumoto, K; Fukuhara, H; Hayashida, Y; Hirama, H; Ikeda, K; Katayama, S; Kato, T; Kobayashi, K; Nagami, T; Nishimura, K; Ohira, S; Shimizu, R; Sugimoto, M; Takamoto, A; Tohi, Y, 2022
)
0.72
" Skin adverse events were graded according to the Common Terminology Criteria for Adverse Events (v5."( Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Dainichi, T; Daizumoto, K; Fukuhara, H; Hayashida, Y; Hirama, H; Ikeda, K; Katayama, S; Kato, T; Kobayashi, K; Nagami, T; Nishimura, K; Ohira, S; Shimizu, R; Sugimoto, M; Takamoto, A; Tohi, Y, 2022
)
0.72
"2%) experienced skin adverse events."( Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Dainichi, T; Daizumoto, K; Fukuhara, H; Hayashida, Y; Hirama, H; Ikeda, K; Katayama, S; Kato, T; Kobayashi, K; Nagami, T; Nishimura, K; Ohira, S; Shimizu, R; Sugimoto, M; Takamoto, A; Tohi, Y, 2022
)
0.72
"Nearly half of the Japanese patients in this study experienced skin adverse events following apalutamide administration."( Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Dainichi, T; Daizumoto, K; Fukuhara, H; Hayashida, Y; Hirama, H; Ikeda, K; Katayama, S; Kato, T; Kobayashi, K; Nagami, T; Nishimura, K; Ohira, S; Shimizu, R; Sugimoto, M; Takamoto, A; Tohi, Y, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"Plasma concentration data for apalutamide and N-desmethyl-apalutamide from 1092 subjects (seven clinical studies) receiving oral apalutamide (30-480 mg) once daily were pooled for a population pharmacokinetic analysis using a non-linear mixed-effect modelling approach."( Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects.
Ackaert, O; Chien, C; Ouellet, D; Pérez-Blanco, JS; Pérez-Ruixo, C; Pérez-Ruixo, JJ; Yu, M, 2020
)
0.56
"A population pharmacokinetic modelling approach was successfully applied to describe the pharmacokinetics of apalutamide and N-desmethyl-apalutamide."( Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects.
Ackaert, O; Chien, C; Ouellet, D; Pérez-Blanco, JS; Pérez-Ruixo, C; Pérez-Ruixo, JJ; Yu, M, 2020
)
0.56
"We applied physiologically based pharmacokinetic modeling for our predictions, and simulated DDI between single-dose and repeated-dose apalutamide 240 mg coadministered with ketoconazole, gemfibrozil, or rifampicin."( Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model.
Chien, C; De Zwart, L; Lopez-Gitlitz, A; Monshouwer, M; Ouellet, D; Snoeys, J; Van den Bergh, A; Ward, P, 2020
)
0.56
" Serial blood samples for pharmacokinetic analysis were collected on C1D7 and C2D8."( Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Abrams, C; Attard, G; Chi, KN; Chien, C; de Jonge, MJA; de Wit, R; Friedlander, TW; Hellemans, P; Jiao, JJ; Posadas, EM; Saad, F; Yu, MK, 2020
)
0.56
" No clinically significant pharmacokinetic interaction was observed between abiraterone and apalutamide; however, apalutamide decreased exposure to prednisone."( Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Abrams, C; Attard, G; Chi, KN; Chien, C; de Jonge, MJA; de Wit, R; Friedlander, TW; Hellemans, P; Jiao, JJ; Posadas, EM; Saad, F; Yu, MK, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
"Two phase I studies assessed the drug-drug interaction potential of apalutamide as a substrate and perpetrator."( Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.
Armas, D; Bulat, I; Carles, J; Chien, C; Duran, I; Hellemans, P; Jiao, J; Mitselos, A; Ward, P, 2020
)
0.56
"We aimed to predict CYP3A4 and CYP2C8 inhibitor/inducer effects on the steady-state pharmacokinetics of apalutamide and total potency-adjusted pharmacologically active moieties, and simulated drug-drug interaction (DDI) between single-dose and repeated-dose apalutamide coadministered with known inhibitors/inducers."( Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model.
Chien, C; De Zwart, L; Lopez-Gitlitz, A; Monshouwer, M; Ouellet, D; Snoeys, J; Van den Bergh, A; Ward, P, 2020
)
0.56
" Therefore, we investigated the characteristics of autophagic response to ARN-509 treatment and evaluated the potential effect of a combination with autophagy inhibition."( Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
Eberli, D; Kranzbühler, B; Mortezavi, A; Salemi, S; Sulser, T, 2020
)
0.56
" Cells were treated with ARN-509 (50 µM) alone or in combination with the autophagy inhibitors 3-methyladenine (3MA, 5 mM) or chloroquine (Chl, 20 µM) or with ATG5 siRNA knock-down."( Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
Eberli, D; Kranzbühler, B; Mortezavi, A; Salemi, S; Sulser, T, 2020
)
0.56
" Furthermore, in combination with autophagy inhibitors, ARN-509 provided a significantly elevated antitumor effect, thus providing a new therapeutic approach potentially translatable to patients."( Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
Eberli, D; Kranzbühler, B; Mortezavi, A; Salemi, S; Sulser, T, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"The aim of the present work was to design a pH-modified solid dispersion (pH(M)-SD) that can improve the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug."( Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo.
Fan, Y; Gao, C; Ge, Z; Gong, W; He, S; Huang, X; Shan, L; Tong, Y; Wang, Y; Yang, M, 2014
)
0.4
"In this phase 1 study, the absolute bioavailability and absorption, metabolism, and excretion (AME) of apalutamide, a competitive inhibitor of the androgen receptor, were evaluated in 12 healthy men."( Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes.
Chien, C; Cuyckens, F; de Vries, R; Jacobs, F; Mannens, G; Snoeys, J; Ward, P, 2019
)
0.51
" The results showed that proxalutamide had good oral bioavailability and wide tissue distribution in vivo."( Quantitative determination of proxalutamide in rat plasma and tissues using liquid chromatography/tandem mass spectrometry.
Gu, S; Peng, Y; Sang, H; Sun, J; Wang, G; Wang, Y; Zhong, Y, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" In the N3 nitrogen-substituted series one compound, 5,5-diphenyl-N3-n-butyl-2-thiohydantoin, DPBTH (7), showed promise during initial screening, but when analyzed in a dose-response study, its activity was considerably less than that of the parent compound DPTH."( 5,5-Diaryl-2-thiohydantoins and 5,5-diaryl-N3-substituted-2-thiohydantoins as potential hypolipidemic agents.
Tompkins, JE, 1986
)
0.64
" 1 week later (Cycle 1 Day1), after reassessing safety, continuous daily dosing (4 weeks/cycle; once-daily orally) was initiated."( An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Hashine, K; Imanaka, K; Iwaki, Y; Oyama, R; Tsuchiya, T; Uemura, H; Yamaguchi, A, 2019
)
0.51
" Thus, it was ascertained to be an adequate dosage regimen in Japanese mCRPC patients."( An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Hashine, K; Imanaka, K; Iwaki, Y; Oyama, R; Tsuchiya, T; Uemura, H; Yamaguchi, A, 2019
)
0.51
"Radiation dose-response viability and clonogenic assays showed that apalutamide had a stronger radio-sensitising activity for all three cell lines."( Apalutamide radio-sensitisation of prostate cancer.
Giatromanolaki, A; Kakouratos, C; Kalamida, D; Koukourakis, MI; Lamprou, I; Nanos, C; Xanthopoulou, E, 2021
)
0.62
", low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients."( Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.
Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glycogen phosphorylase, muscle formOryctolagus cuniculus (rabbit)Ki5.10000.02504.89039.0000AID1333320
Glycogen phosphorylase, liver formHomo sapiens (human)Ki5.10000.40002.75005.1000AID1333320
Glutaminyl-peptide cyclotransferaseHomo sapiens (human)IC50 (µMol)390.00005.00005.00005.0000AID1893771
Protein cereblonHomo sapiens (human)IC50 (µMol)332.00000.28601.70663.0000AID1685005
Protein cereblonHomo sapiens (human)Ki169.00001.49006.580010.0000AID1685005
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
glycogen metabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
5-phosphoribose 1-diphosphate biosynthetic processGlycogen phosphorylase, liver formHomo sapiens (human)
response to bacteriumGlycogen phosphorylase, liver formHomo sapiens (human)
glucose homeostasisGlycogen phosphorylase, liver formHomo sapiens (human)
necroptotic processGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferaseGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein modification processGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
purine nucleobase bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
ATP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glucose bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
AMP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
vitamin bindingGlycogen phosphorylase, liver formHomo sapiens (human)
bile acid bindingGlycogen phosphorylase, liver formHomo sapiens (human)
identical protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
zinc ion bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
glutaminyl-peptide cyclotransferase activityGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular regionGlycogen phosphorylase, liver formHomo sapiens (human)
cytosolGlycogen phosphorylase, liver formHomo sapiens (human)
secretory granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, liver formHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, liver formHomo sapiens (human)
extracellular regionGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
specific granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
extracellular exosomeGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
tertiary granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
ficolin-1-rich granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID648277Inhibition of Dengue virus NS2B-NS3 protease using Abz-NleKRRS-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins measured every sec for 15 mins by fluorimetric analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
AID648279Inhibition of Escherichia coli MurA using PEP as substrate assessed as inorganic phosphate release at 25 uM preincubated for 10 mins measured after 60 mins by fluorimetric assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
AID1333320Competitive inhibition of rabbit muscle glycogen phosphorylase-b in presence of varying glucose-1-phosphate levels and NADP2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthetic, enzyme kinetic, and protein crystallographic studies of C-β-d-glucopyranosyl pyrroles and imidazoles reveal and explain low nanomolar inhibition of human liver glycogen phosphorylase.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
AID1685005Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence by MST based assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID648278Inhibition of bovine plasma thrombin using Boc-Val-Pro-Arg-AMC as substrate at 25 uM preincubated for 15 mins measured after 10 mins by fluorimetric assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
AID648280Inhibition of Escherichia coli MetAP at 10 uM after 15 mins by fluorescence analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (430)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990118 (27.44)18.7374
1990's24 (5.58)18.2507
2000's33 (7.67)29.6817
2010's124 (28.84)24.3611
2020's131 (30.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.53 (24.57)
Research Supply Index6.21 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index41.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials45 (9.91%)5.53%
Reviews61 (13.44%)6.00%
Case Studies6 (1.32%)4.05%
Observational1 (0.22%)0.25%
Other341 (75.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]